Regular physical exercise normalizes elevated asymmetrical dimethylarginine concentrations in patients with Type 1 diabetes mellitus

Wiener Klinische Wochenschrift

Volumn 117, Issue 23-24, 2005, Pages 816-820

  Mittermayer, Friedrich ^a   Pleiner, Johannes ^a   Krzyzanowska, Katarzyna ^b   Wiesinger, Günther F ^a   Francesconi, Mario ^c   Wolzt, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^c Rehabilitation Center Alland   (Austria)

Author keywords

Asymmetrical dimethylarginine; Cardiovascular risk; Exercise; Type 1 diabetes mellitus

Indexed keywords

N(G),N(G) DIMETHYLARGININE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; EXERCISE; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE; MALE; PHYSICAL ACTIVITY; RISK FACTOR;

ADULT; ARGININE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; EXERCISE THERAPY; FEMALE; HUMANS; MALE; TREATMENT OUTCOME;

EID: 32144434069     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-005-0476-y     Document Type: Article

References (43)

1. Vallance P (2003) Nitric oxide: therapeutic opportunities. Fundam Clin Pharmacol 17: 1-10
2. Vallance P, Leone A, Calver A, Collier J, Moncada S (1992) Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 20 [Suppl 12]: S60-62
3. Chan NN, Chan JC (2002) Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia 45: 1609-1616
4. Vallance P, Leone A, Calver A, Collier J, Moncada S (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575
5. Böger RH, Lentz SR, Bode-Böger SM, Knapp HR, Haynes WG (2001) Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) 100: 161-167
6. Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH (2003) Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 361: 1511-1517
7. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al (1998) Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98: 1842-1847
8. Hörl WH (2003) Atherosclerosis and uremia: signifance of non-traditional risk factors. Wien Klin Wochenschr 115: 220-234
9. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, et al (1999) Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33: 652-658
10. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, et al (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358: 2113-2117
11. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, et al (2001) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358: 2127-2128
12. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA (1993) Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 88: 2510-2516
13. Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I (2003) Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 166: 279-284
14. Krolewski AS, Kosinski EJ, Warram JH, Stevens Leland O, Busick EJ, Cader Asmal A, et al (1987) Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 59: 750-755
15. Fuchsjäger-Mayrl G, Pleiner J, Wiesinger GF, Sieder AE, Quittan M, Nuhr MJ, et al (2002) Exercise training improves vascular endothelial function in patients with type 1 diabetes. Diabetes Care 25: 1795-1801
16. Wiesinger GF , Pleiner J, Quittan M, Fuchsjäger-Mayrl G, Crevenna R, Nuhr MJ, et al (2001) Health related quality of life in patients with long-standing insulin dependent (type 1) diabetes mellitus: benefits of regular physical training. Wien Klin Wochenschr 113: 670-675
17. Lehmann R, Kaplan V, Bingisser R, Bloch KE, Spinas GA (1997) Impact of physical activity on cardiovascular risk factors in IDDM. Diabetes Care 20: 1603-1611
18. Pleiner J, Wolzt M (2001) Train your endothelium. Wien Klin Wochenschr 113: 635-637
19. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA (2002) Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 303: 131-137
20. Mittermayer F, Namiranian K, Pleiner J, Schaller G, Wolzt M (2004) Acute Escherichia coli endotoxaemia decreases the plasma 1-arginine/asymmetrical dimethylarginine ratio in humans. Clin Sci (Lond) 106: 577-581
21. Chan NN, Vallance P, Colhoun HM (2003) Endothelium-dependent and -independent vascular dysfunction in type 1 diabetes: role of conventional risk factors, sex, and glycemic control. Arterioscler Thromb Vasc Biol 23: 1048-1054
22. Böger RH (2003) Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med 41: 1467-1472
23. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, et al (2004) Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 24: 1682-1688
24. Calver A, Collier J, Vallance P (1992) Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 90: 2548-2554
25. Mittermayer F, Schaller G, Pleiner J, Vychytil A, Sunder-Plassmann G, Hörl WH, et al (2005) Asymmetrical dimethylarginine plasma concentrations are related to basal nitric oxide release but not endothelium-dependent vasodilation of resistance arteries in peritoneal dialysis patients. J Am Soc Nephrol 16: 1832-1838
26. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC (2003) Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 24: 1912-1919
27. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH (2004) Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 27: 765-769
28. Niebauer J, Clark AL, Webb-Peploe KM, Boger R, Coats AJ (2005) Home-based exercise training modulates prooxidant substrates in patients with chronic heart failure. Eur J Heart Fail 7: 183-188
29. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, et al (2003) Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23: 1455-1459
30. Ogawa T, Kimoto M, Sasaoka K (1989) Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 264: 10205-10209
31. Kimoto M, Tsuji H, Ogawa T, Sasaoka K (1993) Detection of NG,NG-dimethylarginine dimethylaminohydrolase in the nitric oxide-generating systems of rats using monoclonal antibody. Arch Biochem Biophys 300: 657-662
32. Zaletel J, Cerne D, Lenart K, Zitta S, Jurgens G, Estelberger W, et al (2004) Renal functional reserve in patients with Type 1 diabetes mellitus. Wien Klin Wochenschr 116: 246-251
33. Fukai T, Siegfried MR, Ushio-Fukai M, Cheng Y, Kojda G, Harrison DG (2000) Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J Clin Invest 105: 1631-1639
34. Davison GW, George L, Jackson SK, Young IS, Davies B, Bailey DM, et al (2002) Exercise, free radicals, and lipid peroxidation in type 1 diabetes mellitus. Free Radic Biol Med 33: 1543-1551
35. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al (2002) Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106: 987-992
36. Böger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, et al (2000) LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circulation Research 87: 99-105
37. Ligtenberg PC, Blans M, Hoekstra JB, van der Tweel I, Erkelens DW (1999) No effect of long-term physical activity on the glycemic control in type 1 diabetes patients: a cross-sectional study. Neth J Med 55: 59-63
38. Wallberg-Henriksson H, Gunnarsson R, Henriksson J, DeFronzo R, Felig P, Ostman J, et al (1982) Increased peripheral insulin sensitivity and muscle mitochondrial enzymes but unchanged blood glucose control in type I diabetics after physical training. Diabetes 31: 1044-1050
39. Zinman B, Zuniga-Guajardo S, Kelly D (1984) Comparison of the acute and long-term effects of exercise on glucose control in type I diabetes. Diabetes Care 7: 515-519
40. Landt KW, Campaigne BN, James FW, Sperling MA (1985) Effects of exercise training on insulin sensitivity in adolescents with type I diabetes. Diabetes Care 8: 461-465
41. Mittermayer F, Mayer BX, Meyer A, Winzer C, Pacini G, Wagner OF, et al (2002) Circulating concentrations of asymmetrical dimethyl-L-arginine are increased in women with previous gestational diabetes. Diabetologia 45: 1372-1378
42. Paiva H, Lehtimaki T, Laakso J, Ruokonen I, Rantalaiho V, Wirta O, et al (2003) Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 52: 303-307
43. Valkonen VP, Laakso J, Paiva H, Lehtimaki T, Lakka TA, Isomustajarvi M, et al (2003) Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? Atheroscler [Suppl] 4: 19-22